Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

AstraZeneca (AZN.L)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (p) Price Target (p) Rating
2020-11-2777707300Sell
2020-11-3078057500Neutral
2021-02-2570108000Buy
2021-06-1783839200Buy
2021-10-19873910000Buy
2022-03-07865110500Buy
2022-06-14975010100Neutral
2023-02-211157011900Neutral
2023-05-151200012500Neutral
2023-07-121024813000Buy
2024-01-151085210700Sell
2024-02-0997619900Sell

Disclosures

  • UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
  • This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-investment banking securities-related services are being, or have been, provided.
  • Within the past 12 months, UBS has received compensation for products and services other than investment banking services from this company/entity.
  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.